Breast Cancer

Julie Nangia, MD, gives advice for patients expecting to lose their hair as a result of chemotherapy.

Scalp cooling to reduce, or prevent, chemotherapy-induced hair loss has not been utilized as frequently in the US as elsewhere around the world.

A recent study indicates that having a strong social network could improve survival of patients with breast cancer.

Women experiencing symptoms of menopause are less likely to adhere to treatment.

According to a recent study, postmenopausal women with early-stage breast cancer may be at risk of cardiovascular disease from aromatase inhibitor therapy.

Modern scalp-cooling system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.

According to findings from a phase II trial, prophylactic treatment with a combination of loperamide and budesonide reduced the rate of all-grade diarrhea associated with neratinib to 65%, compared with 95.4% observed in the ExteNET trial.

According to phase II trial findings, adding everolimus to fulvestrant significantly improved progression-free survival for postmenopausal patients with metastatic hormone receptor-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.

SHARE's video series featuring women with metastatic breast cancer.

SHARE online support communities for patients with ovarian cancer, breast cancer, and metastatic breast cancer.

Krista Qualmann discusses the nurse's role once a patient has gone for genetic testing.

Kathy LaTour shares her holiday experience with cancer and the tips she's learned since.

Recent research highlights the unmet psychological needs for older breast cancer survivors.

Vitamin D in women with breast cancer has been linked to a better prognosis, especially for women who are premenopausal.

Expert Kristin Zorn, MD discusses the importance that genetics plays in oncology, and the why genetic counseling and testing are vital.

Non-lump and non-breast symptoms of breast cancer occur for 1 in 6 women with breast cancer. For those women, patient intervals to a diagnosis of breast cancer were 1.5 times and 2 times longer.

Dr. Erin Hofstatter gives some "red flags" that indicate a patient or family member should consider genetic counseling and testing.

For women with breast cancer receiving adjuvant endocrine therapy (AET), adherence may depend on socioeconomic status and out-of-pocket costs.

Genetic testing can be used to stratify the risk of a patient experiencing complications during cancer, such as venous thromboembolism (VTE).

Dr. Debu Tripathy discusses the common treatments to help prevent recurrence of early stage breast cancer.

Dr. Elena Ratner discusses the interaction between menopause and certain treatments for breast cancer.

Despite previous thought, working night shifts does not increase the risk of breast cancer.

Stressing self care, a Mei Fu developed an online platform for prevention and treatment of lymphedema.

The Society for Gynecologic Oncology (SGO) released a toolkit of case studies and resources on genetic testing for healthcare providers, patients, and their families.

Survivorship expert Jennifer Klemp talks about optimal survivorship care, the contents of a survivorship plan, measurement of progress and the financial considerations.

An update on CDK4 and CDK6 inhibitors in treatment for patients with metastatic breast cancer.

For patients with HR-positive breast cancer, fulvestrant proved to be better for PFS than anastrozole.

Erin Hofstatter, MD, discusses the important risks and benefits to consider when deciding on preventive surgery for patients at high-risk for breast cancer.

When Breast Cancer Awareness Month arrives each October, for many women there is a lot to be thankful for. Research advances have led to less aggressive treatment options and a good prognosis for women with early-stage disease, but for women with metastatic breast cancer (MBC), it is a different story.